drugset / Trial / NCT06643390

A Study of MK-2225 in Healthy Participants (MK-2225-003)

NCT06643390 ↗

Phase 1 Completed 32 enrolled Merck Sharp & Dohme LLC
RandomizedSequentialDouble-blindTreatment

Summary

The purpose of the study is to learn about the safety of MK-2225, including how well people tolerate it. Researchers also want to learn what happens to different doses of MK-2225 in a person's body over time.

Timeline

Start
2023-11-21
Primary completion
2025-07-14
Completion
2025-07-14

Drugs

EvaluationDrugModalityDoseRoute
Subject MK-2225 Unknown — Subcutaneous

Indications